Data I/O (DAIO) Competitors $3.21 +0.01 (+0.31%) Closing price 03:57 PM EasternExtended Trading$3.22 +0.00 (+0.16%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAIO vs. NAUT, PRE, INTT, OPXS, ODYS, AKYA, OMIC, OPTX, AATC, and CLIRShould you be buying Data I/O stock or one of its competitors? The main competitors of Data I/O include Nautilus Biotechnology (NAUT), Prenetics Global (PRE), inTEST (INTT), Optex Systems (OPXS), Odysight.ai (ODYS), Akoya Biosciences (AKYA), Singular Genomics Systems (OMIC), Syntec Optics (OPTX), Autoscope Technologies (AATC), and ClearSign Technologies (CLIR). These companies are all part of the "measuring and control equipment" industry. Data I/O vs. Its Competitors Nautilus Biotechnology Prenetics Global inTEST Optex Systems Odysight.ai Akoya Biosciences Singular Genomics Systems Syntec Optics Autoscope Technologies ClearSign Technologies Data I/O (NASDAQ:DAIO) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Do analysts prefer DAIO or NAUT? Data I/O currently has a consensus price target of $5.22, indicating a potential upside of 62.62%. Nautilus Biotechnology has a consensus price target of $2.13, indicating a potential upside of 193.06%. Given Nautilus Biotechnology's higher probable upside, analysts plainly believe Nautilus Biotechnology is more favorable than Data I/O.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Data I/O 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Nautilus Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media favor DAIO or NAUT? In the previous week, Nautilus Biotechnology had 1 more articles in the media than Data I/O. MarketBeat recorded 2 mentions for Nautilus Biotechnology and 1 mentions for Data I/O. Nautilus Biotechnology's average media sentiment score of 0.47 beat Data I/O's score of 0.47 indicating that Nautilus Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Data I/O 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in DAIO or NAUT? 37.0% of Data I/O shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 2.6% of Data I/O shares are held by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, DAIO or NAUT? Data I/O has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Which has stronger valuation and earnings, DAIO or NAUT? Data I/O has higher revenue and earnings than Nautilus Biotechnology. Data I/O is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioData I/O$21.77M1.36-$3.09M-$0.29-11.07Nautilus BiotechnologyN/AN/A-$70.78M-$0.54-1.34 Is DAIO or NAUT more profitable? Nautilus Biotechnology has a net margin of 0.00% compared to Data I/O's net margin of -12.21%. Data I/O's return on equity of -14.56% beat Nautilus Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Data I/O-12.21% -14.56% -10.84% Nautilus Biotechnology N/A -31.87%-27.39% SummaryNautilus Biotechnology beats Data I/O on 8 of the 15 factors compared between the two stocks. Get Data I/O News Delivered to You Automatically Sign up to receive the latest news and ratings for DAIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DAIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAIO vs. The Competition Export to ExcelMetricData I/OELEC IndustryComputer SectorNASDAQ ExchangeMarket Cap$29.66M$4.98B$28.45B$9.41BDividend YieldN/A2.97%3.09%4.04%P/E Ratio-11.0731.7233.5919.84Price / Sales1.362.231,804.1499.59Price / CashN/A22.7037.8657.94Price / Book1.682.257.635.65Net Income-$3.09M$171.53M$779.03M$258.00M7 Day Performance2.72%0.87%2.35%2.09%1 Month Performance6.64%3.58%7.48%11.13%1 Year Performance17.58%-3.60%52,761.55%18.40% Data I/O Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAIOData I/O1.6195 of 5 stars$3.21+0.3%$5.22+62.6%+14.3%$29.66M$21.77M-11.07100Positive NewsUpcoming EarningsNAUTNautilus Biotechnology3.0181 of 5 stars$0.80-2.9%$2.13+167.0%-73.5%$103.44MN/A-1.47130PREPrenetics Global1.8735 of 5 stars$8.01+0.1%$9.00+12.4%+39.2%$97.64M$30.62M-2.011INTTinTEST3.3974 of 5 stars$7.32+2.5%$12.00+63.9%-35.4%$91.46M$127.50M31.83320News CoverageOPXSOptex Systems2.1208 of 5 stars$11.94-0.7%N/A+51.1%$83.16M$33.99M16.8280ODYSOdysight.ai1.9238 of 5 stars$4.70-3.1%$10.00+112.8%N/A$79.14M$3.96M-4.6140Gap UpAKYAAkoya Biosciences2.3644 of 5 stars$1.29-5.1%$2.51+94.3%N/A$67.94M$81.67M-1.3390Gap UpOMICSingular Genomics SystemsN/A$20.01flat$6.50-67.5%N/A$50.83M$2.91M-0.57220OPTXSyntec Optics0.546 of 5 stars$1.38+0.7%N/A-29.4%$50.26M$29.44M0.003News CoveragePositive NewsGap UpAATCAutoscope Technologies1.9437 of 5 stars$7.50flatN/A+12.9%$41.18M$12.89M8.5240CLIRClearSign Technologies2.2216 of 5 stars$0.54flat$2.00+272.4%-41.9%$28.16M$3.60M-4.4810News CoverageGap Up Related Companies and Tools Related Companies Nautilus Biotechnology Competitors Prenetics Global Competitors inTEST Competitors Optex Systems Competitors Odysight.ai Competitors Akoya Biosciences Competitors Singular Genomics Systems Competitors Syntec Optics Competitors Autoscope Technologies Competitors ClearSign Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAIO) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTurn $1K into $50K with This DeFi GemTHREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Data I/O Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Data I/O With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.